In Vitro Treatment of Chemotherapy Resistant Human Ovarian Cancer by Administration of CPE

What is the purpose of this trial?

Using Clostridium perfringens enterotoxin (CPE), to target ovarian cancer cells based on their high levels of claudin-3 and -4 potentially represents a novel, highly effective therapeutic approach to treat metastatic and/or chemotherapy-resistant ovarian cancer.


Participation Guidelines

Gender: Both


Yale Cancer Center

Dates: 05/29/2008 - 04/04/2012

Last Updated: 07/31/2015

Study HIC#: 0804003671

Clinical Trial

How will my information be used?
For more information, contact:
Martha Luther
(425) 123-4567
martha.luther@yale.edu

Principal Investigators

Alessandro D. Santin

Principal Investigator

Dan-Arin Silasi

Sub-Investigator

Masoud Azodi

Sub-Investigator

Stefania Bellone

Sub-Investigator

Peter E Schwartz

Sub-Investigator